<?xml version='1.0' encoding='utf-8'?>
<document id="17089108"><sentence text="Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan."><entity charOffset="100-110" text="Olanzapine" /><entity charOffset="115-126" text="Samidorphan" /></sentence><sentence text="A combination of the antipsychotic olanzapine and the opioid receptor antagonist samidorphan (OLZ/SAM) is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain"><entity charOffset="35-45" text="olanzapine" /><entity charOffset="54-60" text="opioid" /><entity charOffset="81-92" text="samidorphan" /><entity charOffset="94-97" text="OLZ" /><entity charOffset="98-101" text="SAM" /><entity charOffset="156-166" text="olanzapine" /><entity charOffset="184-194" text="olanzapine" /></sentence><sentence text=" As cytochrome P450 (CYP) 1A2 and CYP3A4 are the major enzymes involved in metabolism of olanzapine and samidorphan, respectively, physiologically-based pharmacokinetic (PBPK) modeling was applied to predict any drug-drug interaction (DDI) potential between olanzapine and samidorphan or between OLZ/SAM and CYP3A4/CYP1A2 inhibitors/inducers"><entity charOffset="89-99" text="olanzapine" /><entity charOffset="104-115" text="samidorphan" /><entity charOffset="258-268" text="olanzapine" /><entity charOffset="273-284" text="samidorphan" /></sentence><sentence text=" A PBPK model for OLZ/SAM was developed and validated by comparing model-simulated data with observed clinical study data" /><sentence text=" Based on model-based simulations, no DDI between olanzapine and samidorphan is expected when administered as OLZ/SAM"><entity charOffset="50-60" text="olanzapine" /><entity charOffset="65-76" text="samidorphan" /></sentence><sentence text=" CYP3A4 inhibition is predicted to have a weak effect on samidorphan exposure and negligible effect on olanzapine exposure"><entity charOffset="57-68" text="samidorphan" /><entity charOffset="103-113" text="olanzapine" /></sentence><sentence text=" CYP3A4 induction is predicted to reduce both samidorphan and olanzapine exposure"><entity charOffset="46-57" text="samidorphan" /><entity charOffset="62-72" text="olanzapine" /></sentence><sentence text=" CYP1A2 inhibition or induction is predicted to increase or decrease, respectively, olanzapine exposure only"><entity charOffset="84-94" text="olanzapine" /></sentence><sentence text="" /></document>